Coordinating Care Between Dermatologists and Rheumatologists to Improve Outcomes in Patients with Psoriatic Arthritis
Click Here To Download Faculty Response to Questions from the Live Webcast (PDF)Premiere Date: Friday, May 1, 2015
This activity offers CE credit for:%>
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, May 1, 2016
Note: Credit Is No Longer Available
|April W. Armstrong, MD, MPH (Moderator)
Associate Dean, Clinical Research
Professor of Dermatology
Director, Clinical Research Support, Southern California CTSI
Keck School of Medicine
University of Southern California
Los Angeles, CA
|David G. Borenstein, MD, MACP, MACR
Clinical Professor of Medicine
Division of Rheumatology
The George Washington University Medical Center
|Joel M. Gelfand, MD, MSCE
Professor of Dermatology and Epidemiology
Vice Chair of Clinical Research
Medical Director, Dermatology Clinical Studies Unit
Director, Psoriasis and Phototherapy Treatment Center
University of Pennsylvania Perelman School of Medicine
Psoriatic arthritis (PsA) occurs in approximately 30% of patients with psoriasis.1 The skin manifestation of psoriasis precedes joint disease in 85% of patients by an average of 12 years.2 Because of the significant incidence of PsA in patients with psoriasis, and because there is a long delay in the onset of symptoms, it is essential that dermatologists screen for and recognize the early symptoms of PsA.
Communication and care coordination is one of the quality domains of the National Quality Strategy. In alignment with the priorities of the National Quality Strategy, this CME Outfitters Live and On Demand features a panel of key specialists—dermatologists and a rheumatologist—involved in the coordination of care for patients with PsA. These experts in psoriasis and PsA will engage the audience in a live discussion that will help practicing clinicians recognize the early signs of PsA and implement screening techniques, discuss recommendations for the treatment of moderate-to-severe PsA, and advise on when and how to collaborate with rheumatologists in the management of moderate-to-severe PsA. The audience will have the opportunity to be active participants in the discussion live polling and a live, 30-minute Q&A session via phone, email, fax, or Twitter, all with the goal of improving outcomes in patients with PsA.
- Cleveland Clinic Monograph. Exploring Care for Psoriatic Arthritis: Bridging Dermatology and Rheumatology. The Cleveland Clinic Website. http://www.clevelandclinicmeded.com/online/monograph/psoriatic- arthritis/Psoriatic-Monograph.pdf. Published October 28, 2009. Accessed March 17, 2015.
- Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58(5):851-864. PMID: 18423261.
This educational activity centers on the CME Outfitters Make One Change statement. This statement is crafted from pertinent quality measures or clinical guidelines as a performance challenge to all participants. The Make One Change statement for this activity is:
Treat psoriatic arthritis according to treatment guidelines in more than 50% of my patients in the next three months.
At the end of this CE activity, participants should be able to:
- Implement screening guidelines to ensure 75% of my patients with psoriasis are screened for psoriatic arthritis in the next three months.
- Apply professional treatment guidelines in more than 50% of my patients with psoriatic arthritis in the next three months.
- Coordinate care and consult with rheumatologists for more than 50% of my patients with moderate or severe psoriatic arthritis in the next three months.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Review screening guidelines for psoriatic arthritis in patients with psoriasis.
- Define treatment guidelines for patients with psoriatic arthritis.
- Examine ways to coordinate care with rheumatologists in patients with moderate-to-severe PsA.
Supported by educational grants from Celgene Corporation and Novartis Pharmaceuticals Corporation.
Dermatologists, rheumatologists, internists, primary care physicians, physician assistants, nurse practitioners, nurses, pharmacists, and other health care providers that manage or counsel patients with psoriatic arthritis.
CME Credit (Physicians):
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours.
Note to Nurse Practitioners and Clinical Nurse Specialists: the content of this activity pertains to pharmacology. Earn up to 1.5 contact hours of pharmacotherapeutic contact hours.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs)
Universal Activity Number: 0376-0000-15-010-L01-P (live programs)
0376-0000-15-010-H01-P (recorded programs)
Activity Type: knowledge-based
Disclosure of Relevant Financial Relationships with Commercial Interests
USF Health and CME Outfitters, LLC, adhere to the ACCME Standards, as well as those of the ACPE, APA, and ANCC, regarding commercial support of continuing medical education. It is the policy of USF Health and CME Outfitters, LLC, that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved, and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation.
A conflict of interest is created when individuals in a position to control the content of CME have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
USF Health and CME Outfitters will identify, review, and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant financial relationships exist between the following individuals and commercial interests:
Dr. Armstrong has disclosed that she has received research and grant support from Amgen Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. She serves as a consultant for AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Pharmaceuticals, Inc.
Dr. Borenstein has disclosed that he serves on the advisory board of AbbVie Inc.; Amgen Inc.; Iroko Pharmaceuticals, LLC; Pfizer Inc.; and is a consultant to Janssen Pharmaceuticals, Inc. He has received other financial or material support from the Board of Directors, Patient Access Network.
Dr. Gelfand has disclosed that he has received (or has pending) research and grant support from AbbVie Inc.; Amgen Inc.; Eli Lilly and Company; Janssen Biologics, Inc. (formerly Centocor Biotech, Inc.); Novartis Corporation; and Pfizer Inc. He serves as a consultant for AbbVie Inc.; Amgen Inc.; Celgene Corporation; Eli Lilly and Company; Endo Pharmaceuticals Inc.; Janssen Biologics, Inc. (formerly Centocor Biotech, Inc.); Merck & Co., Inc.; Novartis Corporation; Pfizer Inc.
Erica Perilstein, MD (peer reviewer) has nothing to disclose.
Ruth Cody, MSN, RN-BC, CBN (peer reviewer) has nothing to disclose.
Frances Daniel, MPH (planning committee) has nothing to disclose.
Sandra Haas Binford, MAEd (planning committee) has nothing to disclose.
Sharon Tordoff, CCMEP (Activity Director and planning committee) has nothing to disclose.
Disclosures were obtained from the CME Outfitters, LLC staff: Nothing to disclose.
Disclosures were obtained from the USF Health OCPD staff: Nothing to disclose.
Disclosures are on file at the USF Health, Office of Continuing Professional Development and with CME Outfitters.
There is no fee to participate in or claim CME/CE credit for this activity.
The OCPD has security measures in place to protect the loss, misuse, and alteration of the information under our control. The OCPD does not share or sell any individual's contact information, financial information, or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.
If you have credit related queries or complaints, please contact USF Health by email, firstname.lastname@example.org, call 813.224.7860, or visit www.cme.hsc.usf.edu.
USF is an Equal Opportunity/ Equal Access/ Affirmative Action Institution.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).